ACRV Acrivon Therapeutics, Inc.
$2.00▼ -1.96%
Healthcare
Other
After hours
$2.00▲ +0.00%
Sep 11, 7:30 PM ET
Volume 461.6K
Avg Volume (10D) 204.6K
Key Metrics & Fundamentals
Market Cap
$85.71M
P/E Ratio
–
Div Yield
–%
52W Range
1.27 - 3.56
% vs 50 MA
6.04%
% vs 200 MA
8.11%
RSI-14
49.9
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.98
Free Cash Flow
-$14.95M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.26M
COGS
–
Operating Exp
$18.67M
Operating Income
-$18.67M
EBIT
-$18.67M
Pretax Income
-$17.96M
Net Income
-$17.96M
EPS (Diluted)
-0.43
Price & Volume History
Loading chart…
Recent News

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Zacks · Sep 3, 2026 1:55 PM

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · Sep 2, 2026 12:00 PM

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
GlobeNewswire · Aug 31, 2026 12:30 PM

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Zacks · Aug 24, 2026 4:00 PM

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
GlobeNewswire · Aug 12, 2026 8:05 PM
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
GlobeNewswire · Aug 5, 2026 12:30 PM
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
GlobeNewswire · Jul 21, 2026 8:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ACRV's money flow as a full page
Social Sentiment
No Reddit posts found for ACRV.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.